Orunmila Pharma, Inc_Presentation
•Download as PPTX, PDF•
2 likes•236 views
Orunmila Pharma has developed small peptide therapeutics derived from HIV-1 that target the HSP-70 family members mortalin and DnaK for the treatment of cancer, viral infections, inflammation, and bacterial infection with low toxicity. They have been granted multiple patents and filed several patent applications related to the composition and use of these small membrane-regulating region (SMR) peptides that demonstrate efficacy by binding to and inhibiting mortalin and DnaK.
Report
Share
Report
Share
Recommended
Radiation Enhances the Invasiveness of Irradiated and Nonirradiated Bystander...
This study investigated how radiation enhances the invasiveness of irradiated and non-irradiated hepatoma cells through a VEGF-MMP2 pathway initiated by p53. The results showed that: (1) Irradiation up-regulated MMP2 activity and VEGF secretion via a p53-regulated pathway, promoting cell invasion; (2) VEGF secreted from irradiated cells was responsible for inducing invasiveness in non-irradiated bystander cells through a p53-dependent mechanism; (3) Invasiveness in irradiated cells depended on enhanced p53, MMP2 and VEGF, while invasiveness in bystander cells depended on MMP2, VEGF2 from bystander cells and
High Sensitivity Detection of Tumor Gene Mutations-v3
This document summarizes a new method called QClamp PCR that can highly sensitively detect tumor gene mutations. QClamp uses synthetic XNA probes to selectively block amplification of wild-type DNA sequences, improving the sensitivity of PCR to detect mutations present in less than 0.1% of samples. This level of sensitivity allows detection of mutations from biopsy, tissue, or blood samples. The document discusses applications of QClamp PCR for detection of EGFR mutations in lung cancer patients and enriching samples for DNA sequencing. QClamp represents an improvement over other methods by reducing the excess of wild-type DNA that creates high background signals.
Th1_Towards the fine mapping of the major QTL conferring resistance to Africa...
Th1_Towards the fine mapping of the major QTL conferring resistance to Africa...Africa Rice Center (AfricaRice)
3rd Africa Rice Congress
Theme 1: Climate resilient rice
Mini symposium: Towards improved resistance to biotic stressesBrain stroming
1) Gene knockout of CCR5 chemokine co-receptor prevents HIV entry into target cells by knocking out the CCR5 gene which codes for the CCR5 receptor.
2) Gene knockin alters the CCR5 genomic sequence to produce an altered CCR5 that prevents viral entry while maintaining normal CCR5 function.
3) Genetic mutations open the door to new possibilities, as evidenced by the ability to alter CCR5 and prevent HIV infection while preserving CCR5's role in cell communication.
Tri-Con_2015
1) The document describes QClamp XNA-PCR, a technology from DiaCarta that uses molecular "clamps" to highly sensitively detect low frequency and cell-free circulating mutant DNA.
2) It needs assays that can detect biomarkers present at low frequency in samples containing a high amount of normal DNA. Existing technologies are inadequate for this need.
3) QClamp assays can reliably detect all possible mutations in a gene region using a single reaction. They can achieve ultra-high sensitivity down to 0.01% from minimal sample input.
Tcr Technology - Creative Biolabs
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
Chims poster
This document describes the validation of a new STR-based assay using the Eurochimerism (EUC) primer set to detect chimerism in bone marrow transplant patients. The validation showed that the assay can reliably detect chimerism levels down to 5-10% by analyzing control samples containing varying percentages of donor DNA. Results from patient samples tested with both the new EUC assay and the previous assay were over 90% concordant, demonstrating that the new assay meets the diagnostic accuracy standards required for clinical use.
Shu
This document summarizes various drug transport mechanisms in cancer cells and their role in drug resistance and efficacy. It discusses uptake and efflux mechanisms, intracellular transport pathways, and how modulating these mechanisms through inhibitors can increase drug permeability in brain tumors and enhance treatment outcomes. Specific transporters and signaling pathways involved in determining permeability are also reviewed, along with their impact on drug response.
Recommended
Radiation Enhances the Invasiveness of Irradiated and Nonirradiated Bystander...
This study investigated how radiation enhances the invasiveness of irradiated and non-irradiated hepatoma cells through a VEGF-MMP2 pathway initiated by p53. The results showed that: (1) Irradiation up-regulated MMP2 activity and VEGF secretion via a p53-regulated pathway, promoting cell invasion; (2) VEGF secreted from irradiated cells was responsible for inducing invasiveness in non-irradiated bystander cells through a p53-dependent mechanism; (3) Invasiveness in irradiated cells depended on enhanced p53, MMP2 and VEGF, while invasiveness in bystander cells depended on MMP2, VEGF2 from bystander cells and
High Sensitivity Detection of Tumor Gene Mutations-v3
This document summarizes a new method called QClamp PCR that can highly sensitively detect tumor gene mutations. QClamp uses synthetic XNA probes to selectively block amplification of wild-type DNA sequences, improving the sensitivity of PCR to detect mutations present in less than 0.1% of samples. This level of sensitivity allows detection of mutations from biopsy, tissue, or blood samples. The document discusses applications of QClamp PCR for detection of EGFR mutations in lung cancer patients and enriching samples for DNA sequencing. QClamp represents an improvement over other methods by reducing the excess of wild-type DNA that creates high background signals.
Th1_Towards the fine mapping of the major QTL conferring resistance to Africa...
Th1_Towards the fine mapping of the major QTL conferring resistance to Africa...Africa Rice Center (AfricaRice)
3rd Africa Rice Congress
Theme 1: Climate resilient rice
Mini symposium: Towards improved resistance to biotic stressesBrain stroming
1) Gene knockout of CCR5 chemokine co-receptor prevents HIV entry into target cells by knocking out the CCR5 gene which codes for the CCR5 receptor.
2) Gene knockin alters the CCR5 genomic sequence to produce an altered CCR5 that prevents viral entry while maintaining normal CCR5 function.
3) Genetic mutations open the door to new possibilities, as evidenced by the ability to alter CCR5 and prevent HIV infection while preserving CCR5's role in cell communication.
Tri-Con_2015
1) The document describes QClamp XNA-PCR, a technology from DiaCarta that uses molecular "clamps" to highly sensitively detect low frequency and cell-free circulating mutant DNA.
2) It needs assays that can detect biomarkers present at low frequency in samples containing a high amount of normal DNA. Existing technologies are inadequate for this need.
3) QClamp assays can reliably detect all possible mutations in a gene region using a single reaction. They can achieve ultra-high sensitivity down to 0.01% from minimal sample input.
Tcr Technology - Creative Biolabs
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
Chims poster
This document describes the validation of a new STR-based assay using the Eurochimerism (EUC) primer set to detect chimerism in bone marrow transplant patients. The validation showed that the assay can reliably detect chimerism levels down to 5-10% by analyzing control samples containing varying percentages of donor DNA. Results from patient samples tested with both the new EUC assay and the previous assay were over 90% concordant, demonstrating that the new assay meets the diagnostic accuracy standards required for clinical use.
Shu
This document summarizes various drug transport mechanisms in cancer cells and their role in drug resistance and efficacy. It discusses uptake and efflux mechanisms, intracellular transport pathways, and how modulating these mechanisms through inhibitors can increase drug permeability in brain tumors and enhance treatment outcomes. Specific transporters and signaling pathways involved in determining permeability are also reviewed, along with their impact on drug response.
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
This document discusses next generation epigenetic profiling and biomarkers. It provides an overview of epigenetics and methylation in oncology. MDxHealth is developing next-generation epigenetic biomarkers including methylation-based companion diagnostics. Deep sequencing techniques like MBD-Seq are being used to discover biomarkers from genome-wide methylation profiling and provide high resolution of methylation heterogeneity. Validation studies of biomarkers like MGMT promoter methylation are also discussed.
EASL2015cfDNA2
This document summarizes a study examining circulating free tumor DNA (cfDNA) as a diagnostic biomarker for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in Nigerian patients. The study found that cfDNA levels were higher in patients with HCC compared to non-HCC patients, and that cfDNA concentration alone had moderate accuracy for diagnosing HCC. The diagnostic accuracy was improved when cfDNA concentration was combined with alpha-fetoprotein levels. While the common TP53 gene mutation was found in HCC patients, detection of this mutation had lower diagnostic utility than cfDNA concentration alone or combined with AFP. The study concludes that cfDNA quantification alone or combined with AFP may be useful for
GKA deel 2 college 12
Bartlett and Moore discuss improving HIV therapy through the development of new drug classes and highly active antiretroviral therapy (HAART). HAART involves combining three drugs, often including a protease inhibitor, to minimize viral load. This helps reduce damage to CD4 cells and development of drug resistance. New drug classes target different parts of the HIV lifecycle, including reverse transcriptase, integrase and protease. While HAART can prolong the latent period, therapy aims to control the virus, not cure it, and challenges remain around adherence, side effects and development of drug resistance.
Indo-SA HIVR4P
This document summarizes research into developing an anti-HIV vaccine using nucleoside-modified mRNA encoding envelope proteins. Key points:
- Researchers developed mRNA vaccines optimized for protein expression by incorporating modified nucleosides, UTRs, caps, and tails to generate HIV envelope proteins.
- Mice were primed with intradermal mRNA followed by an intramuscular protein boost to achieve strong T cell and B cell responses.
- The mRNA vaccine induced high levels of IFN-γ, TNF-α, IL-2 in antigen-specific T cells and antibody titers, demonstrating the potential of nucleoside-modified mRNA vaccines for infectious diseases like HIV.
Development and verification of an Ion AmpliSeq TP53 Panel
A large amount of data is available on the functional impact of missense mutations in TP53 tumor suppressor gene. and on mutation patterns in many different cancers. TP53 direct sequencing is a time-consuming method with limitations in detection level. Here we describe the development and verification of a TP53 Next Generation Sequencing method based on Ion AmpliSeq technology. Preliminary data demonstrate that the TP53 Ion AmpliSeq panel and Ion Reporter Software analysis solution meets the requirements of clinical research laboratories.
OS16 - 2.P3.a The Role of Asymptomatic Carriers in FMD Ecology; Unifying Kn...
OS16 - Open Session 2016
Cascais, Portugal
26 - 28 /10/2016
EuFMD Sessions\Open Session\Archive-2018\Open 2016 Cascais- Portugal\PPT presentations\
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)
1. CXCR4 is a chemokine receptor that binds to its ligand SDF1. It plays roles in HIV infection, cancer metastasis, hematopoiesis, and organogenesis.
2. CXCR4 expression and signaling is regulated by transcription factors, cytokines, growth factors, and G protein coupling. Dysregulation of CXCR4 contributes to diseases like WHIM syndrome and various cancers.
3. In cancer, CXCR4 upregulation enhances migration and adhesion, possibly facilitating metastasis. CXCR4 expression provides survival advantages for some cancer cells through interactions with the tumor microenvironment.
What's New in Cancer Treatment; Chemotherapy vs. Targeted Therapy
What's New in Cancer Treatment; Chemotherapy vs. Targeted TherapyProvidence Health & Services Southwest Washington
Presentation by Jim Lechner, MD, for Providence Cancer Survivor Celebration on June 2, 2012 in Olympia, Wash.Abstract
The document summarizes an experiment studying the effects of doxorubicin, a chemotherapy drug, on the expression of prognostic biomarkers in two breast cancer cell lines, MDAMB- 231 and BT-474. The cells were treated with doxorubicin at the determined IC50 concentration for 48 hours. Total RNA was extracted and real-time PCR was used to analyze expression levels of various genes representing different molecular pathways. The results showed varying expression between the two cell lines, with several markers like L, ZN, ZF and AT having the highest expression levels in the BT-474 cell line. The presence of markers such as P-cadherin, Nrf2 and CD44 suggest the cells still exhibited properties of proliferation
nature13121
1) The document reports that 6 out of 16 melanoma tumor samples analyzed acquired expression of EGFR after developing resistance to BRAF or MEK inhibitor drugs.
2) Using a shRNA library targeting chromatin regulators, the researchers found that suppression of SOX10 in melanoma cells leads to activation of TGF-β signaling and upregulation of EGFR and PDGFRB, conferring resistance to BRAF and MEK inhibitors.
3) Expression of EGFR in melanoma cells or treatment with TGF-β results in a slow-growth phenotype with cellular hallmarks of senescence. However, EGFR expression or TGF-β exposure becomes advantageous for proliferation in the presence of BRAF or
an mrna vaccine aganist sars cov 2
- The mRNA-1273 vaccine induced robust antibody and neutralizing responses against SARS-CoV-2 in all participants after the first dose. A second dose led to even stronger responses, especially in the 100 μg and 250 μg groups. Systemic side effects were mostly mild or moderate. This interim report provides support for mRNA-1273 as a promising COVID-19 vaccine candidate warranting further development and evaluation.
Defining the relevant genome in solid tumors
Decades of cancer research including comprehensive molecular profiling combined with the
development of a broad array of targeted therapies have created the opportunity to transform
cancer care in the near future by implementing precision oncology based approaches. An
important element of this system is the widespread availability of robust and cost-effective
multivariate profiling methods in order to characterize relevant cancer associated molecular
alterations.
Current commercially available multivariate profiling methods vary dramatically with regard to
the number of cancer genes interrogated. Given that many large scale and detailed molecular
profiling studies have been completed, the landscape of somatic alterations in solid tumors is
reasonably well-known. Furthermore, the specific gene variants that are relevant to application
of targeted therapies are also a matter of record. Therefore, we set out to define the number of
relevant cancer genes for precision oncology research based on the currently available
empirical evidence.
Cerullo_verona2010_AdenovirusGT
This document provides an overview of adenoviral gene therapy, including its applications and limitations. It discusses how adenovirus can be used as a vector for gene delivery due to its ability to efficiently infect cells and produce high titers. However, high doses of adenoviral vectors can cause toxicity and a lethal inflammatory response due to activation of the innate immune system through receptors like TLRs. The adaptive immune system also responds to adenoviral vectors over time.
1-s2.0-S2211124714001612-main
Three key points:
1. A kinome-centered synthetic lethality screen identified that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors.
2. MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance.
3. Drugs targeting both EGFR and ERBB2, each capable of forming hetero-dimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM.
nature10868
1) BRAF(V600E) inhibition through PLX4032 is effective for treating melanoma but not colon cancer, which shows limited response.
2) A genetic screen identified that inhibiting EGFR synergizes with inhibiting BRAF(V600E) in colon cancer cell lines.
3) Mechanistically, inhibiting BRAF(V600E) causes rapid feedback activation of EGFR through inhibition of MEK/ERK and activation of CDC25C, which supports continued proliferation. Inhibiting both BRAF and EGFR prevents this feedback and synergistically inhibits colon cancer cell and tumor growth.
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Saba Anwer, MPH, MBA
The Quintiles Comprehensive Cancer Panel (QCCP) is a targeted sequencing assay that analyzes genomic variation in 223 cancer, DNA repair, and pharmacogenomic genes using Illumina sequencing platforms. It was analytically validated to CLIA standards, with a sensitivity over 99% for SNVs and indels at certain allele frequencies and a specificity over 99%. The QCCP can detect point mutations, insertions, deletions, and structural rearrangements to help identify biomarkers predictive of response to cancer therapies.An gef mi_scriptffpe
The document summarizes a study that used the miScript PCR System to profile miRNA expression changes in total RNA samples isolated from FFPE normal and tumor lung tissues. Key points:
1) The miScript PCR System, in conjunction with the miRNeasy FFPE Kit, provides a solution for miRNA expression profiling from archived FFPE samples.
2) The study found significant differences in mature miRNA expression levels between normal and tumor lung tissue, consistent with previous studies.
3) The miRNeasy FFPE Kit efficiently extracts total RNA containing miRNA from FFPE samples, and the miScript PCR System provides highly reproducible results across isolations.
Van criekinge next_generation_epigenetic_profling_vvumc_uploaded
This document discusses next generation epigenetic profiling using methylation-based biomarkers. It provides an overview of epigenetics and methylation in oncology. It then discusses MDxHealth's next-generation epigenetic biomarkers and methylation-based companion diagnostics. As an example, it summarizes research on MGMT promoter methylation predicting benefit from DNA-alkylating chemotherapy in glioblastoma patients.
Anti-HIV standard regimens and newer drugs
all the data presented in this presentation is authentic from WHO website and Pharmacology book goodman gillman's Basic of therapeutics
Genotypisation of the microbial agents of hospital infections
This document discusses genotyping methods for identifying nosocomial pathogens. It notes that nosocomial infections cause significant morbidity, mortality, and costs. Various multidrug-resistant bacteria that commonly cause healthcare-associated infections are identified. Understanding the distribution and relatedness of pathogens is important for epidemiology and infection control. Several molecular genotyping methods are described in detail, including pulsed-field gel electrophoresis, ribotyping, plasmid analysis, and PCR-based methods. The use of genotyping at one hospital led to a significant reduction in infections and associated costs and deaths, demonstrating the clinical utility and cost-effectiveness of molecular typing.
Aguardiente
Los aguardientes son bebidas alcohólicas obtenidas por destilación de mostos o pastas fermentadas. Se originaron en Persia y se difundieron durante la época de Alejandro Magno. En Colombia, Cristóbal Colón trajo la caña de azúcar y comenzó la producción de aguardiente. La Fábrica de Licores y Alcoholes de Antioquia es la principal productora de licores y aguardientes en Colombia, con más de noventa años de historia.
Nutrición
Este documento trata sobre una alimentación equilibrada y saludable. Recomienda comer de forma variada alimentos de todos los grupos para obtener los nutrientes necesarios, comer al menos cinco porciones al día, y mantener raciones moderadas para una buena nutrición sin eliminar ningún grupo de alimentos. También enfatiza la importancia de un desayuno balanceado y beber suficientes líquidos además de agua.
More Related Content
What's hot
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
This document discusses next generation epigenetic profiling and biomarkers. It provides an overview of epigenetics and methylation in oncology. MDxHealth is developing next-generation epigenetic biomarkers including methylation-based companion diagnostics. Deep sequencing techniques like MBD-Seq are being used to discover biomarkers from genome-wide methylation profiling and provide high resolution of methylation heterogeneity. Validation studies of biomarkers like MGMT promoter methylation are also discussed.
EASL2015cfDNA2
This document summarizes a study examining circulating free tumor DNA (cfDNA) as a diagnostic biomarker for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) in Nigerian patients. The study found that cfDNA levels were higher in patients with HCC compared to non-HCC patients, and that cfDNA concentration alone had moderate accuracy for diagnosing HCC. The diagnostic accuracy was improved when cfDNA concentration was combined with alpha-fetoprotein levels. While the common TP53 gene mutation was found in HCC patients, detection of this mutation had lower diagnostic utility than cfDNA concentration alone or combined with AFP. The study concludes that cfDNA quantification alone or combined with AFP may be useful for
GKA deel 2 college 12
Bartlett and Moore discuss improving HIV therapy through the development of new drug classes and highly active antiretroviral therapy (HAART). HAART involves combining three drugs, often including a protease inhibitor, to minimize viral load. This helps reduce damage to CD4 cells and development of drug resistance. New drug classes target different parts of the HIV lifecycle, including reverse transcriptase, integrase and protease. While HAART can prolong the latent period, therapy aims to control the virus, not cure it, and challenges remain around adherence, side effects and development of drug resistance.
Indo-SA HIVR4P
This document summarizes research into developing an anti-HIV vaccine using nucleoside-modified mRNA encoding envelope proteins. Key points:
- Researchers developed mRNA vaccines optimized for protein expression by incorporating modified nucleosides, UTRs, caps, and tails to generate HIV envelope proteins.
- Mice were primed with intradermal mRNA followed by an intramuscular protein boost to achieve strong T cell and B cell responses.
- The mRNA vaccine induced high levels of IFN-γ, TNF-α, IL-2 in antigen-specific T cells and antibody titers, demonstrating the potential of nucleoside-modified mRNA vaccines for infectious diseases like HIV.
Development and verification of an Ion AmpliSeq TP53 Panel
A large amount of data is available on the functional impact of missense mutations in TP53 tumor suppressor gene. and on mutation patterns in many different cancers. TP53 direct sequencing is a time-consuming method with limitations in detection level. Here we describe the development and verification of a TP53 Next Generation Sequencing method based on Ion AmpliSeq technology. Preliminary data demonstrate that the TP53 Ion AmpliSeq panel and Ion Reporter Software analysis solution meets the requirements of clinical research laboratories.
OS16 - 2.P3.a The Role of Asymptomatic Carriers in FMD Ecology; Unifying Kn...
OS16 - Open Session 2016
Cascais, Portugal
26 - 28 /10/2016
EuFMD Sessions\Open Session\Archive-2018\Open 2016 Cascais- Portugal\PPT presentations\
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)
1. CXCR4 is a chemokine receptor that binds to its ligand SDF1. It plays roles in HIV infection, cancer metastasis, hematopoiesis, and organogenesis.
2. CXCR4 expression and signaling is regulated by transcription factors, cytokines, growth factors, and G protein coupling. Dysregulation of CXCR4 contributes to diseases like WHIM syndrome and various cancers.
3. In cancer, CXCR4 upregulation enhances migration and adhesion, possibly facilitating metastasis. CXCR4 expression provides survival advantages for some cancer cells through interactions with the tumor microenvironment.
What's New in Cancer Treatment; Chemotherapy vs. Targeted Therapy
What's New in Cancer Treatment; Chemotherapy vs. Targeted TherapyProvidence Health & Services Southwest Washington
Presentation by Jim Lechner, MD, for Providence Cancer Survivor Celebration on June 2, 2012 in Olympia, Wash.Abstract
The document summarizes an experiment studying the effects of doxorubicin, a chemotherapy drug, on the expression of prognostic biomarkers in two breast cancer cell lines, MDAMB- 231 and BT-474. The cells were treated with doxorubicin at the determined IC50 concentration for 48 hours. Total RNA was extracted and real-time PCR was used to analyze expression levels of various genes representing different molecular pathways. The results showed varying expression between the two cell lines, with several markers like L, ZN, ZF and AT having the highest expression levels in the BT-474 cell line. The presence of markers such as P-cadherin, Nrf2 and CD44 suggest the cells still exhibited properties of proliferation
nature13121
1) The document reports that 6 out of 16 melanoma tumor samples analyzed acquired expression of EGFR after developing resistance to BRAF or MEK inhibitor drugs.
2) Using a shRNA library targeting chromatin regulators, the researchers found that suppression of SOX10 in melanoma cells leads to activation of TGF-β signaling and upregulation of EGFR and PDGFRB, conferring resistance to BRAF and MEK inhibitors.
3) Expression of EGFR in melanoma cells or treatment with TGF-β results in a slow-growth phenotype with cellular hallmarks of senescence. However, EGFR expression or TGF-β exposure becomes advantageous for proliferation in the presence of BRAF or
an mrna vaccine aganist sars cov 2
- The mRNA-1273 vaccine induced robust antibody and neutralizing responses against SARS-CoV-2 in all participants after the first dose. A second dose led to even stronger responses, especially in the 100 μg and 250 μg groups. Systemic side effects were mostly mild or moderate. This interim report provides support for mRNA-1273 as a promising COVID-19 vaccine candidate warranting further development and evaluation.
Defining the relevant genome in solid tumors
Decades of cancer research including comprehensive molecular profiling combined with the
development of a broad array of targeted therapies have created the opportunity to transform
cancer care in the near future by implementing precision oncology based approaches. An
important element of this system is the widespread availability of robust and cost-effective
multivariate profiling methods in order to characterize relevant cancer associated molecular
alterations.
Current commercially available multivariate profiling methods vary dramatically with regard to
the number of cancer genes interrogated. Given that many large scale and detailed molecular
profiling studies have been completed, the landscape of somatic alterations in solid tumors is
reasonably well-known. Furthermore, the specific gene variants that are relevant to application
of targeted therapies are also a matter of record. Therefore, we set out to define the number of
relevant cancer genes for precision oncology research based on the currently available
empirical evidence.
Cerullo_verona2010_AdenovirusGT
This document provides an overview of adenoviral gene therapy, including its applications and limitations. It discusses how adenovirus can be used as a vector for gene delivery due to its ability to efficiently infect cells and produce high titers. However, high doses of adenoviral vectors can cause toxicity and a lethal inflammatory response due to activation of the innate immune system through receptors like TLRs. The adaptive immune system also responds to adenoviral vectors over time.
1-s2.0-S2211124714001612-main
Three key points:
1. A kinome-centered synthetic lethality screen identified that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors.
2. MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance.
3. Drugs targeting both EGFR and ERBB2, each capable of forming hetero-dimers with ERBB3, can reverse unresponsiveness to MEK inhibition by decreasing inhibitory phosphorylation of the proapoptotic proteins BAD and BIM.
nature10868
1) BRAF(V600E) inhibition through PLX4032 is effective for treating melanoma but not colon cancer, which shows limited response.
2) A genetic screen identified that inhibiting EGFR synergizes with inhibiting BRAF(V600E) in colon cancer cell lines.
3) Mechanistically, inhibiting BRAF(V600E) causes rapid feedback activation of EGFR through inhibition of MEK/ERK and activation of CDC25C, which supports continued proliferation. Inhibiting both BRAF and EGFR prevents this feedback and synergistically inhibits colon cancer cell and tumor growth.
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Saba Anwer, MPH, MBA
The Quintiles Comprehensive Cancer Panel (QCCP) is a targeted sequencing assay that analyzes genomic variation in 223 cancer, DNA repair, and pharmacogenomic genes using Illumina sequencing platforms. It was analytically validated to CLIA standards, with a sensitivity over 99% for SNVs and indels at certain allele frequencies and a specificity over 99%. The QCCP can detect point mutations, insertions, deletions, and structural rearrangements to help identify biomarkers predictive of response to cancer therapies.An gef mi_scriptffpe
The document summarizes a study that used the miScript PCR System to profile miRNA expression changes in total RNA samples isolated from FFPE normal and tumor lung tissues. Key points:
1) The miScript PCR System, in conjunction with the miRNeasy FFPE Kit, provides a solution for miRNA expression profiling from archived FFPE samples.
2) The study found significant differences in mature miRNA expression levels between normal and tumor lung tissue, consistent with previous studies.
3) The miRNeasy FFPE Kit efficiently extracts total RNA containing miRNA from FFPE samples, and the miScript PCR System provides highly reproducible results across isolations.
Van criekinge next_generation_epigenetic_profling_vvumc_uploaded
This document discusses next generation epigenetic profiling using methylation-based biomarkers. It provides an overview of epigenetics and methylation in oncology. It then discusses MDxHealth's next-generation epigenetic biomarkers and methylation-based companion diagnostics. As an example, it summarizes research on MGMT promoter methylation predicting benefit from DNA-alkylating chemotherapy in glioblastoma patients.
Anti-HIV standard regimens and newer drugs
all the data presented in this presentation is authentic from WHO website and Pharmacology book goodman gillman's Basic of therapeutics
Genotypisation of the microbial agents of hospital infections
This document discusses genotyping methods for identifying nosocomial pathogens. It notes that nosocomial infections cause significant morbidity, mortality, and costs. Various multidrug-resistant bacteria that commonly cause healthcare-associated infections are identified. Understanding the distribution and relatedness of pathogens is important for epidemiology and infection control. Several molecular genotyping methods are described in detail, including pulsed-field gel electrophoresis, ribotyping, plasmid analysis, and PCR-based methods. The use of genotyping at one hospital led to a significant reduction in infections and associated costs and deaths, demonstrating the clinical utility and cost-effectiveness of molecular typing.
What's hot (20)
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
2014 03 28_next_generation_epigenetic_profling_v_les_epigenetica_vweb
Development and verification of an Ion AmpliSeq TP53 Panel
Development and verification of an Ion AmpliSeq TP53 Panel
OS16 - 2.P3.a The Role of Asymptomatic Carriers in FMD Ecology; Unifying Kn...
OS16 - 2.P3.a The Role of Asymptomatic Carriers in FMD Ecology; Unifying Kn...
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)
What's New in Cancer Treatment; Chemotherapy vs. Targeted Therapy
What's New in Cancer Treatment; Chemotherapy vs. Targeted Therapy
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Van criekinge next_generation_epigenetic_profling_vvumc_uploaded
Van criekinge next_generation_epigenetic_profling_vvumc_uploaded
Genotypisation of the microbial agents of hospital infections
Genotypisation of the microbial agents of hospital infections
Viewers also liked
Aguardiente
Los aguardientes son bebidas alcohólicas obtenidas por destilación de mostos o pastas fermentadas. Se originaron en Persia y se difundieron durante la época de Alejandro Magno. En Colombia, Cristóbal Colón trajo la caña de azúcar y comenzó la producción de aguardiente. La Fábrica de Licores y Alcoholes de Antioquia es la principal productora de licores y aguardientes en Colombia, con más de noventa años de historia.
Nutrición
Este documento trata sobre una alimentación equilibrada y saludable. Recomienda comer de forma variada alimentos de todos los grupos para obtener los nutrientes necesarios, comer al menos cinco porciones al día, y mantener raciones moderadas para una buena nutrición sin eliminar ningún grupo de alimentos. También enfatiza la importancia de un desayuno balanceado y beber suficientes líquidos además de agua.
Como subir una presentación a blogger
Este documento proporciona 9 pasos para subir una presentación de PowerPoint a Blogger: 1) crear una nueva entrada en Blogger, 2) hacer clic en el botón HTML, 3) iniciar sesión en SlideShare y subir la presentación, 4) copiar el enlace de la presentación, 5) pegar el enlace en la entrada de Blogger para publicarla.
Evaluacion del impacto ambiental 1
Etapas a considerar en la ingenieria ecologica y las causas del desequilibrio en los diferentes ecosistemas como agua, suelo y atmosfera
Plantilla icontec
Este documento presenta un resumen del proceso de desarrollo del ser humano a través de sus siete etapas: prenatal, infancia, niñez, adolescencia, juventud, adultez y ancianidad. Explica brevemente cada etapa, incluyendo las características y edades que comprenden. El objetivo es mostrar a las personas las diferentes etapas del crecimiento humano para que conozcan más a fondo su cuerpo y desarrollo.
CE-545_Fall 2015_TPG_03_Final_Report
This document is a term paper submitted by Muhammad Daniyal to fulfill the requirements of a Masters in Engineering Management course. The paper assesses the state of design completeness in the construction industry. It identifies factors that lead to major changes in design during construction and causes of delays. The author conducted a literature review and questionnaire survey of industry professionals to gather data. Statistical analysis was performed on the survey responses. Key findings included that design often relies on client briefs that are occasionally provided and frequently changed. Specifications are not consistently tailored for projects. Changes are commonly initiated by clients after design is finalized. The author recommends clients provide clear briefs upfront, standards be adopted for design documentation, and contractor input be obtained earlier to improve
Así está the company... Septiember 2016 Circulo de Empresarios
The document discusses business activity and economic indicators in Spain. It notes that in July 2016, the creation of commercial companies in Spain increased 1.7% year-over-year, with the greatest growth in La Rioja (+85.7%). It also discusses exports, GDP growth, foreign investment in Spain, real estate activity and home prices, credit conditions, and economic perspectives.
Jose platilla
Este documento describe las siete etapas del desarrollo humano: la etapa prenatal, la infancia, la niñez, la adolescencia, la juventud, la adultez y la ancianidad. Detalla las características generales de cada etapa, incluyendo las edades típicas. El objetivo es informar sobre el proceso de desarrollo del ser humano a lo largo de la vida.
INVESTIGACION GOOGLE TRENDS - JULIANA ESCOBAR
El documento habla sobre tres marcas principales de tequila - Tequila Jose Cuervo, Tequila 1800 y Tequila Don Julio. Explica que Tequila Jose Cuervo es la marca más buscada y enumera algunas de las regiones que más buscan esta marca y las otras dos. También menciona algunos de los beneficios para la salud del tequila, como ayudar con la digestión, reducir el colesterol malo y producir efectos relajantes.
Free Amigurumi Patterns
The document introduces several Amigurumi toy models created by different designers, including a caterpillar, curly haired girl, and gardener. It provides the materials, colors, and stitching instructions needed to make each toy. The toys were made using specific yarn brands and colors to teach children and provide an enjoyable activity for mothers.
Peter Pão - Manual de indentidade Visual
This manual provides guidelines for the visual identity of Peter Pão bakery. It describes the brand elements, colors, typography and approved versions of the logo. The logo incorporates elements from milk, wheat, and Peter Pan's hat to represent the bakery's products and fun spirit in a simple, balanced design.
Viewers also liked (13)
Así está the company... Septiember 2016 Circulo de Empresarios
Así está the company... Septiember 2016 Circulo de Empresarios
Similar to Orunmila Pharma, Inc_Presentation
Metastatic HER2 Garcia.pptx
1) HER2 positive breast cancer accounts for around 15-20% of cases and has a poorer prognosis than other subtypes without HER2 targeted therapy.
2) Multiple HER2 targeted agents are available including trastuzumab, lapatinib, pertuzumab, T-DM1, neratinib, and tucatinib which inhibit HER2 signaling through different mechanisms such as antibody binding or tyrosine kinase inhibition.
3) Combining HER2 targeted therapies such as trastuzumab with chemotherapy improves outcomes for patients with metastatic HER2 positive breast cancer compared to chemotherapy alone.
Trans Code Therapeutics Investor Presentation April 2022
TransCode Therapeutics is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas and others. The Company intends to file an exploratory investigational new drug (IND) application for its first in human clinical trial and in parallel complete IND-enabling studies for TTX-MC138 to file an IND for a Phase I/II clinical trial. A second RNAi based program is TTX-siPDL1, a small interfering RNA (siRNA)–based modulator of programmed death-ligand 1 (PD-L1). TransCode also has three cancer agnostic programs—TTX-RIGA, an RNA–based agonist programmed to elicit an immune response against cancer cells; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or deletion of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
nanoparticles in cancer treatment /therpy
this will give an idea about how we can use nanoparticles in cancer drug delivery and how is it better than conventional chemotherapy .
Positive Phase II results for trastuzumab emtansine (T-DM1)
Roche announced positive results from a Phase II trial of trastuzumab emtansine (T-DM1) compared to Herceptin and chemotherapy in previously untreated patients with HER2-positive metastatic breast cancer. Patients receiving T-DM1 lived significantly longer with controlled disease and had fewer side effects than chemotherapy. The trial results support continued development of T-DM1 as a potential new treatment for HER2-positive metastatic breast cancer due to its efficacy and favorable safety profile.
Immunotoxins_MJ.ppt
This document discusses a proposed study to target cancer stem cells in leukemia using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based immunotoxins. The objectives are to identify and characterize cancer stem cells from leukemia cell lines and patients, construct recombinant TRAIL-based chimeric proteins to selectively target these cancer stem cells, and test the efficacy and selectivity of the proteins. Cancer stem cells are resistant to chemotherapy and responsible for leukemia recurrence. TRAIL selectively induces apoptosis in cancer cells and has advantages over chemotherapy. The study aims to develop dual receptor targeted immunotoxins linking TRAIL to the interleukin-2 receptor to more effectively treat leukemia by eliminating drug-resistant cancer stem cells.
Antiviral Drugs and their mechanism of action
Antiviral drugs have been developed since the late 1960s through a process involving discovery, preclinical testing, clinical trials, and regulatory approval. Early antiviral drugs were discovered through random screening of chemicals and natural products. Modern drug discovery utilizes rational drug design based on viral and host targets as well as high-throughput screening of large libraries. Challenges include the narrow spectrum of individual drugs, difficulty targeting intracellular viruses, emergence of resistance, and toxicity. Major classes of antiviral drugs target viral attachment/entry, fusion, uncoating, and replication by inhibiting viral proteins like neuraminidase and M2.
Advanced biotechnological tools for human health care dr shiv om pratap
The document provides an overview of advanced biotechnological tools for human health care. It discusses principles of gene expression and manufacturing of desired products. Some key applications of biotechnology for human health care discussed include molecular marker-based disease diagnosis, gene therapy, disease diagnosis using nucleic acid hybridization, medical forensics using DNA fingerprinting, and various pharmaceutical products produced through biotechnology like recombinant proteins, growth hormone, vaccines, monoclonal antibodies, and assisted reproductive technologies. Transgenic animals and molecular farming approaches are also mentioned as recent advances for human health care.
TransCode Therapeutics Investor Presentation June 2022
TransCode Therapeutics is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas and others. The Company intends to file an exploratory investigational new drug (IND) application for its first in human clinical trial and in parallel complete IND-enabling studies for TTX-MC138 to file an IND for a Phase I/II clinical trial. A second RNAi based program is TTX-siPDL1, a small interfering RNA (siRNA)–based modulator of programmed death-ligand 1 (PD-L1). TransCode also has three cancer agnostic programs—TTX-RIGA, an RNA–based agonist programmed to elicit an immune response against cancer cells; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or deletion of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
Terapia ayurvedica no cancer
This document summarizes several key molecular targets in cancer therapy and discusses how traditional Ayurvedic medicine may provide leads in developing treatments by modulating these targets. It describes major targets like the NF-κB, AP-1, and JAK-STAT pathways that are involved in processes like inflammation, proliferation, apoptosis, and drug resistance. The document then discusses how phytochemicals from plants used in Ayurveda have been shown to suppress many of these same targets and molecular pathways. It suggests Ayurvedic medicine could provide insights on new therapeutic agents if rediscovered in light of modern knowledge of cancer biology.
Gtc presentation 2
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
Key developments in HIV/TB research
Harder-to-treat and more lethal tubercle bacilli continue to emerge across the globe, especially in the African region. Together with HIV, these infectious killers continue to have profound effects on the productive workforce in different countries. The deck is a brief overview of developments in disease management and research, with an emphasis on medications and vaccines.
Lancet Oncology 2004
This document discusses gene therapy approaches for prostate cancer that have been investigated. It outlines several strategies, including delivering genes to induce cell death or inhibit cell growth, activate the immune system against tumor cells, and target specific gene expression. Clinical trials are evaluating therapies using the herpes simplex virus gene with ganciclovir to activate a prodrug, as well as other approaches to manipulate cell proliferation, apoptosis, angiogenesis, and the immune response. Tissue-specific delivery and regulation of gene expression offer promise for gene therapy in prostate cancer.
Targeted Therapies in Cancer
This document discusses targeted cancer therapies, which work by interfering with specific molecular targets involved in cancer growth and progression, unlike traditional chemotherapy which acts on all rapidly dividing cells. It provides examples of molecular targets for small molecule drugs and monoclonal antibodies, including growth factor receptors and fusion proteins. The document also discusses methods of target identification, categories of targeted therapies, examples of FDA-approved targeted drugs, limitations and side effects of targeted therapies, and concludes by emphasizing the importance and promise of targeted therapies while noting challenges that remain.
Hao Liu Resume 2017-02
Hao Liu has over 15 years of experience in drug discovery research. He has developed biochemical and cell-based assays to screen for oncology and metabolic disease targets. He is skilled in developing and optimizing high throughput screening assays, cell signaling studies, and molecular biology techniques. Liu has authored several publications and presented at conferences.
Humanized IT.pptx
Immunotoxins are being developed to specifically target and destroy cancer cells. The document summarizes research from Professor Rama Verma's lab on developing humanized immunotoxins as alternatives to bacterial/toxin-based immunotoxins that can cause toxicity. The lab has created immunotoxins linking GM-CSF to DFF40 to target leukemia cells and IL2 to TRAIL to target leukemia patients' samples. These humanized immunotoxins induce apoptosis in cancer cells with less toxicity than traditional immunotoxins. The lab is also exploring targeting cancer stem cells, which can cause cancer recurrence after treatment.
Protein targets in Mycobacterium tuberculosis and their inhibitors for therap...
Protein targets in Mycobacterium tuberculosis and their inhibitors for therap...Souparnika Sreelatha
Advancement in the area of anti-tubercular drug development has been full-fledged, yet, a very less number of
drug molecules have reached phase II clinical trials, and therefore “End-TB” is still a global challenge. Inhibitors
to specific metabolic pathways of Mycobacterium tuberculosis (Mtb) gain importance in strategizing antituberculosis
drug discovery. The lead compounds that target DNA replication, protein synthesis, cell wall
biosynthesis, bacterial virulence and energy metabolism are emerging as potential chemotherapeutic options
against Mtb growth and survival within the host. In recent times, the in silico approaches have become most
promising tools in the identification of suitable inhibitors for specific protein targets of Mtb. An update in the
fundamental understanding of these inhibitors and the mechanism of interaction may bring hope to future
perspectives in novel drug development and delivery approaches. This review provides a collective impression of
the small molecules with potential antimycobacterial activities and their target pathways in Mtb such as cell wall
biosynthesis, DNA replication, transcription and translation, efflux pumps, antivirulence pathways and general
metabolism. The mechanism of interaction of specific inhibitor with their respective protein targets has been
discussed. The comprehensive knowledge of such an impactful area of research would essentially reflect in the
discovery of novel drug molecules and effective delivery approaches. This narrative review encompasses the
knowledge of emerging targets and promising chemical inhibitors that could potentially translate in to the anti-
TB-drug discovery.Sequencing in management of Multiple sclerosis
Sequencing of DMTs for individual multiple sclerosis patients should be designed in such a way to maximize disease control and minimize risk based on the mechanism of action, pharmacokinetic and pharmacodynamic properties of each therapy. This includes the DMT patients are being switched from to those they are being switched to. The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more prominently in decision making as newer treatments become available for the prevention of disability accumulation in patients with progressive MS. In this short review, we discuss the landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing. While no cure exists for MS, efforts are being directed toward research in neuroregeneration with the hope for positive outcomes.
Advances-in-cancer-research.pdf
The document discusses several technologies and approaches for advancing cancer research by addressing limitations of current methodologies. It describes a new technology called the NanoString GeoMx Digital Spatial Profiler that enables high-plex spatial analysis of biological samples using fluorescently labeled antibodies. It also discusses the development of customized morphology markers to help users select biologically relevant regions of interest for analysis. Additionally, it covers several other areas of cancer research including the use of stem cells for treatment, automated counting of immune cells, development of drug antibodies and therapies targeting GPCRs, and blocking immune checkpoint molecules to stimulate anti-tumor immune responses.
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell linesProf. Eric Raymond Oncologie Medicale
This paper was presented at the EORTC-NCI-AACR meeting last week. The poster shows data on NOTCH expression in cell lines and evaluated the effects of NOCH inhibition.Similar to Orunmila Pharma, Inc_Presentation (20)
Trans Code Therapeutics Investor Presentation April 2022
Trans Code Therapeutics Investor Presentation April 2022
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Positive Phase II results for trastuzumab emtansine (T-DM1)
Positive Phase II results for trastuzumab emtansine (T-DM1)
Advanced biotechnological tools for human health care dr shiv om pratap
Advanced biotechnological tools for human health care dr shiv om pratap
TransCode Therapeutics Investor Presentation June 2022
TransCode Therapeutics Investor Presentation June 2022
Protein targets in Mycobacterium tuberculosis and their inhibitors for therap...
Protein targets in Mycobacterium tuberculosis and their inhibitors for therap...
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Involvement of Notch signaling pathway in a panel of human cancer cell lines
Orunmila Pharma, Inc_Presentation
- 1. Orunmila Pharma, Inc First in class HIV-1 derived small peptides that target HSP-70 family member Mortalin and DnaK as therapeutic for cancer, viral replication, inflammation and bacterial infection with little to no toxicity . Vincent C. Bond, PhD; CEO and President Ming Bo Huang, MD; CRO
- 2. Technology: • Mortalin/HSPA9 and DnaK (HSP70) antagonists for the treatment of cancer, inflammation, and infections. Issued Patents: • US 8,431,530; US 8,476,237; US 8,551,943; US 8,563,506; US 8,669,226; EP 2440570, DE602010009528.2. Patent Applications: • US 13/267,977; US 13/327,244; CA 2,761,121; JP 2012-514976; CN 201080025184.7; HK 12108236.3; IN 8365/CHENP/2011; PCT US2011/055219, and PCT/US11/065137. Applications: • A dominant and expanding patent position for the composition and use of SMR (& derivatives). • Treatment of cancer, viral infected, and inflammatory cells that over-express mortalin. • Treatment of antibiotic resident bacteria that express DnaK. Value Proposition: • Demonstrated efficacy i) mortalin-SMR binding; ii) reduction in exosome secretion; iii) induction of cancer cell, but not “normal” cell death, iv) reduction in HIV particle secretion; and v) bacterial growth inhibition. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 250x103 500x103 750x103 3x106 5x106 8x106 1e+5 1e+6 1e+7 SMRwt peptide in Jurkat SMRmt peptide in Jurkat SMRwt has no toxic effect on target cells growth.
- 3. Summary Nef (Negative Regulatory Factor) is a protein expressed by primate lentiviruses and a virulence factor able to manipulate host cell machinery. Regions interact with multiple host factors including CXCR4. We identified the SMR as a virus-ended secretion modification region that inhibits an intracellular target HSP 70 family member called mortalin (HSPA9, glucose-regulated protein 75 [GRP75], and peptide-binding protein protein 74 [PBP74]). Mortalin plays an important role in cell proliferation. The SMR peptide, developed by our group, binds with pM affinity to mortalin, and nM affinity to bacteria DnaK acting as an antagonist. It has little toxic effect on target cells. MSM was the first to demonstrate efficacy of HIV-1 derived peptides as therapeutics for cancer, viral replication, inflammation and bacterial infection. SMRwtSMRmut